Annual report [Section 13 and 15(d), not S-K Item 405]

Asset Purchase Agreements (Details)

v3.26.1
Asset Purchase Agreements (Details) - USD ($)
 1 Months Ended 12 Months Ended
May 13, 2024
Jul. 28, 2023
Feb. 28, 2025
Jun. 30, 2024
Dec. 31, 2025
Dec. 31, 2024
Asset Purchase Agreements            
Proceeds from the sale of property and equipment     $ 1,200,000   $ 1,165,000 $ 0
June 2024 Repurchase of Assets            
Asset Purchase Agreements            
Accrued interest         33,000  
Total purchase consideration       $ 4,700,000    
Purchase price       1,400,000    
Upfront payment       100,000    
Subsequent payment       $ 1,300,000 1,300,000  
Subsequent amount, due period from closing date       12 months    
Amount of net assets below this threshold, the Company may elect to delay payment obligation by additional six months       $ 20,000,000 $ 20,000,000  
Extension term for deferred payment       6 months    
Interest rate on outstanding Deferred Amount       5.00%    
Period from which interest accrual if deferred amount is not paid       12 months    
Fair value provided from valuation services less costs to sell       $ 2,200,000    
Purchase consideration allocated to the supplies repurchased       2,500,000    
Supplies repurchased with no alternate future use recognized as research and development expense       $ 2,500,000    
uBriGene            
Asset Purchase Agreements            
Proceeds from the sale of property and equipment   $ 6,000,000        
Gain on sale of property and equipment   1,400,000        
Sale consideration considered deferred income   $ 300,000        
Equipment assets purchased term 180 days